6533b7d4fe1ef96bd1261e23

RESEARCH PRODUCT

Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions on treatment? Reply to Dr Mazza and colleagues.

Luigi CalvoRosario ScaglioneG. LicataSalvatore Corrao

subject

medicine.medical_specialtybusiness.industryGinkgo bilobamedicine.diseaselaw.inventionDouble blindNeurologyRandomized controlled trialDouble-Blind MethodPiperidineslawAlzheimer DiseaseIndansmedicineDementiaHumansAlzheimer s dementiaDementiaDonepezilNeurology (clinical)Cholinesterase InhibitorsPsychiatrybusinessRandomized Controlled Trials as Topic10.1111/j.1468-1331.2007.01713.xhttps://pubmed.ncbi.nlm.nih.gov/16930364